Sensus Healthcare, Inc. (NASDAQ:SRTS) Sees Large Increase in Short Interest

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 583,500 shares, a growth of 20.0% from the November 30th total of 486,100 shares. Currently, 4.4% of the shares of the company are short sold. Based on an average trading volume of 174,600 shares, the days-to-cover ratio is currently 3.3 days.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. HC Wainwright increased their price objective on shares of Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, November 18th. Maxim Group boosted their target price on shares of Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, November 15th.

Sensus Healthcare Stock Performance

Shares of NASDAQ:SRTS opened at $7.17 on Tuesday. The stock’s 50-day simple moving average is $7.62 and its two-hundred day simple moving average is $6.58. The stock has a market capitalization of $117.51 million, a price-to-earnings ratio of 12.58 and a beta of 1.16. Sensus Healthcare has a 52-week low of $2.36 and a 52-week high of $9.33.

Hedge Funds Weigh In On Sensus Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP increased its holdings in Sensus Healthcare by 128.0% during the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after buying an additional 93,511 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Sensus Healthcare by 34.4% during the 2nd quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock valued at $2,087,000 after acquiring an additional 100,294 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Sensus Healthcare in the 2nd quarter worth $156,000. Sachetta LLC raised its holdings in Sensus Healthcare by 12.9% in the 2nd quarter. Sachetta LLC now owns 118,354 shares of the company’s stock worth $631,000 after purchasing an additional 13,544 shares during the period. Finally, Marshall Wace LLP lifted its position in Sensus Healthcare by 152.4% during the second quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock valued at $412,000 after purchasing an additional 46,732 shares in the last quarter. Hedge funds and other institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.